[1] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209
[2] 郑荣寿,陈茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46(3):221
ZHENG RS, CHEN R, HAN BF, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol,2024,46(3):221
[3] 中华医学会消化内镜学分会结直肠学组. 中国结直肠癌及癌前病变内镜诊治共识(2023,广州)[J]. 中华消化内镜杂志,2023,40(7):505
Colorectal Group, Digestive Endoscopy Branch of Chinese Medical Association. Expert consensus on endoscopic diagnosis and treatment for colorectal cancer and precancerous lesions in China (2023, Guangzhou)[J]. Clin J Dig Endosc,2023,40(7):505
[4] SINICROPE FA. Increasing incidence of early-onset colorectal cancer[J]. N Engl J Med,2022,386(16):1547
[5] SIEGEL RL, WAGLE NS, CERCEK A, et al.Colorectal cancer statistics, 2023[J]. CA Cancer J Clin,2023,73(3):233
[6] SNINSKY JA, SHORE BM, LUPU GV, et al. Risk factors for colorectal polyps and cancer[J]. Gastrointest Endosc Clin North Am,2022,32(2):195
[7] DEKKER E, TANIS PJ, VLEUGELS JLA, et al. Colorectal cancer[J]. Lancet,2019,394(10207):1467
[8] LIN JS, PERDUE LA, HENRIKSON NB, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force[J]. JAMA,2021,325(19):1978
[9] ZYGULSKA AL, PIERZCHALSKI P. Novel diagnostic biomarkers in colorectal cancer[J]. Int J Mol Sci,2022,23(2):852
[10] LI N, LU B, LUO C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and Northern America[J]. Cancer Lett,2021,522:255
[11] CHAN SCH, LIANG JQ. Advances in tests for colorectal cancer screening and diagnosis[J]. Expert Rev Mol Diagn,2022,22(4):449
[12] SALMERóN AM, TRISTÁN AI, ABREU AC, et al. Serum colorectal cancer biomarkers unraveled by NMR metabolomics: past, present, and future[J]. Anal Chem,2022,94(1):417
[13] SEDLAK JC, YILMAZ ÖH, ROPER J. Metabolism and colorectal cancer[J]. Annu Rev Pathol,2023,18:467
[14] LI J, CHENG B, XIE H, et al. Bladder cancer biomarker screening based on non-targeted urine metabolomics[J]. Int Urol Nephrol,2022,54(1):23
[15] DREW DA, KLEMPNER SJ, CHAN AT. Metabolomics as a tool for biomarker discovery in gastric cancer[J]. Cancer Epidemiol Biomarkers Prev,2021,30(9):1601
[16] AZAD RK, SHULAEV V. Metabolomics technology and bioinformatics for precision medicine[J]. Brief Bioinform,2019,20(6):1957
[17] MARTIAS C, BAROUKH N, MAVEL S, et al. Optimization of sample preparation for metabolomics exploration of urine, feces, blood and saliva in humans using combined NMR and UHPLC-HRMS platforms[J]. Molecules,2021,26(14):4111
[18] LIU L, AA J, WANG G, et al. Differences in metabolite profile between blood plasma and serum[J]. Anal Biochem,2010,406(2):105
[19] NI Y, XIE G, JIA W. Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery[J]. J Proteome Res,2014,13(9):3857
[20] GU J, XIAO Y, SHU D, et al. Metabolomics analysis in serum from patients with colorectal polyp and colorectal cancer by 1H-NMR spectrometry[J]. Dis Markers,2019. doi: 10. 1155/2019/3491852. eCollection 2019.
[21] BIAN X, QIAN Y, TAN B, et al. In-depth mapping carboxylic acid metabolome reveals the potential biomarkers in colorectal cancer through characteristic fragment ions and metabolic flux[J]. Anal Chim Acta,2020,1128:62
[22] DI GIOVANNI N, MEUWIS MA, LOUIS E, et al. Specificity of metabolic colorectal cancer biomarkers in serum through effect size[J]. Metabolomics,2020,16(8):88
[23] AMIR HASHIM NA, AB-RAHIM S, WAN NGAH WZ]. Global metabolomics profiling of colorectal cancer in Malaysian patients[J]. Bioimpacts,2021,11(1):33
[24] ZHANG C, ZHOU S, CHANG H, et al. Metabolomic profiling identified serum metabolite biomarkers and related metabolic pathways of colorectal cancer[J]. Dis Markers,2021.doi: 10.1155/2021/6858809. eCollection 2021
[25] GAO R, WU C, ZHU Y, et al. Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites[J]. Gastroenterology,2022,163(4):1024
[26] YUAN Y, YANG C, WANG Y, et al. Functional metabolome profiling may improve individual outcomes in colorectal cancer management implementing concepts of predictive, preventive, and personalized medical approach[J]. EPMA J,2022,13(1):39
[27] SHU X, XIANG YB, ROTHMAN N, et al. Prospective study of blood metabolites associated with colorectal cancer risk[J]. Int J Cancer,2018,143(3):527
[28] BARBERINI L, RESTIVO A, NOTO A, et al. A gas chromatography-mass spectrometry (GC-MS) metabolomic approach in human colorectal cancer (CRC): the emerging role of monosaccharides and amino acids[J]. Ann Transl Med,2019,7(23):727
[29] GEIJSEN AJMR, BREZINA S, KESKI-RAHKONEN P, et al. Plasma metabolites associated with colorectal cancer: a discovery-replication strategy[J]. Int J Cancer,2019,145(5):1221
[30] KIM S, YIN X, PRODHAN MAI, et al. Global plasma profiling for colorectal cancer-associated volatile organic compounds: a proof-of-principle study[J]. J Chromatogr Sci,2019,57(5):385
[31] ASANTE I, PEI H, ZHOU E, et al. Exploratory metabolomic study to identify blood-based biomarkers as a potential screen for colorectal cancer[J]. Mol Omics,2019,15(1):21
[32] LIU T, TAN Z, YU J, et al. A conjunctive lipidomic approach reveals plasma ethanolamine plasmalogens and fatty acids as early diagnostic biomarkers for colorectal cancer patients[J]. Expert Rev Proteomics,2020,17(3):233
[33] GUMPENBERGER T, BREZINA S, KESKI-RAHKONEN P. Untargeted metabolomics reveals major differences in the plasma metabolome between colorectal cancer and colorectal adenomas[J]. Metabolites,2021,11(2):119
[34] KIM ER, KWON HN, NAM H, et al. Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer[J]. Sci Rep,2019,9(1):4786
[35] DENG L, ISMOND K, LIU Z, et al. Urinary metabolomics to identify a unique biomarker panel for detecting colorectal cancer: a multicenter study[J]. Cancer Epidemiol Biomarkers Prev,2019,28(8):1283
[36] DENG Y, YAO H, CHEN W, et al. Profiling of polar urine metabolite extracts from Chinese colorectal cancer patients to screen for potential diagnostic and adverse-effect biomarkers[J]. J Cancer,2020,11(23):6925
[37] ZHU C, HUANG F, LI Y, et al. Distinct urinary metabolic biomarkers of human colorectal cancer[J]. Dis Markers,2022. doi: 10. 1155/2022/1758113. eCollection 2022
[38] NANNINI G, MEONI G, TENORI L, et al. Fecal metabolomic profiles: a comparative study of patients with colorectal cancer vs adenomatous polyps[J]. World J Gastroenterol,2021,27(38):6430
[39] TELLERIA O, ALBONIGA OE, CLOS-GARCIA M, et al. A comprehensive metabolomics analysis of fecal samples from advanced adenoma and colorectal cancer patients[J]. Metabolites,2022,12(6):550
[40] COKER OO, LIU C, WU WKK, et al. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers[J]. Microbiome,2022,10(1):35
[41] KIBI M, NISHIUMI S, KOBAYASHI T, et al. GC/MS and LC/MS-based tissue metabolomic analysis detected increased levels of antioxidant metabolites in colorectal cancer[J]. Kobe J Med Sci,2019,65(1):E19
[42] KANG C, ZHANG J, XUE M, et al. Metabolomics analyses of cancer tissue from patients with colorectal cancer[J]. Mol Med Rep,2023,28(5):219
[43] TEVINI J, EDER SK, HUBER-SCHÖNAUER U, et al. Changing metabolic patterns along the colorectal adenoma-carcinoma sequence[J]. J Clin Med,2022,11(3):721
[44] TROISI J, TAFURO M, LOMBARDI M, et al. A metabolomics-based screening proposal for colorectal cancer[J]. Metabolites,2022,12(2):110
[45] ZHENG W, WANG M, CHAI X, et al. Targeted metabolomics analysis of nucleosides and the identification of biomarkers for colorectal adenomas and colorectal cancer[J]. Front Mol Biosci,2023.doi: 10. 3389/fmolb. 2023. 1163089. eCollection 2023.
[46] GUO J, PAN Y, CHEN J, et al. Serum metabolite signatures in normal individuals and patients with colorectal adenoma or colorectal cancer using UPLC-MS/MS method[J]. J Proteomics, 2023. doi: 10.1016/j.jprot.2022.104741. Epub 2022 Sep 26.
[47] YI Y, WANG J, LIANG C, et al. LC-MS-based serum metabolomics analysis for the screening and monitoring of colorectal cancer[J]. Front Oncol,2023. doi: 10. 3389/fonc. 2023. 1173424. eCollection 2023.
[48] MCCULLOUGH ML, HODGE RA, CAMPBELL PT, et al. Pre-diagnostic circulating metabolites and colorectal cancer risk in the cancer prevention study-Ⅱ nutrition cohort[J]. Metabolites, 2021,11(3):156
[49] PAPADIMITRIOU N, GUNTER MJ, MURPHY N, et al. Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies[J]. Int J Cancer, 2021,149(9):1659
[50] CORADDUZZA D, ARRU C, CULEDDU N, et al. Quantitative metabolomics to explore the role of plasma polyamines in colorectal cancer[J]. Int J Mol Sci,2022,24(1):101
[51] ZHAO Z, BAI J, LIU C, et al. Metabolomics analysis of amino acid and fatty acids in colorectal cancer patients based on tandem mass spectrometry[J]. J Clin Biochem Nutr,2023,73(2):161
[52] XING F, ZHENG R, LIU B, et al. A new strategy for searching determinants in colorectal cancer progression through whole-part relationship combined with multi-omics[J]. Talanta,2023. doi: 10.1016/j.talanta.2023.124543.
[53] LIN Y, MA C, BEZABEH T, et al. 1H NMR-based metabolomics reveal overlapping discriminatory metabolites and metabolic pathway disturbances between colorectal tumor tissues and fecal samples[J]. Int J Cancer,2019,145(6):1679
[54] WANG Z, CUI B, ZHANG F, et al. Development of a correlative strategy to discover colorectal tumor tissue derived metabolite biomarkers in plasma using untargeted metabolomics[J]. Anal Chem,2019,91(3):2401
[55] ZHU G, WANG Y, WANG W, et al. Untargeted GC-MS-based metabolomics for early detection of colorectal cancer[J]. Front Oncol,2021. doi: 10. 3389/fonc. 2021. 729512. eCollection 2021.
[56] LI C, LI K, XU X, et al. A pilot study for colorectal carcinoma screening by instant metabolomic profiles using conductive polymer spray ionization mass spectrometry[J]. Biochim Biophys Acta Mol Basis Dis,2021,1867(11):166210
